Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

• the invention concerns novel 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV).
• RSV respiratory syncytial virus
• the invention further concerns the preparation of such novel compounds, compositions comprising these compounds, and the compounds for use in the treatment of respiratory syncytial virus infection.
• Human RSV or Respiratory Syncytial Virus is a large RNA virus, member of the family of Paramyxoviridae, subfamily pneumoviridae together with bovine RSV virus.
• Human RSV is responsible for a spectrum of respiratory tract diseases in people of all ages throughout the world. It is the major cause of lower respiratory tract illness during infancy and childhood. Over half of all infants encounter RSV in their first year of life, and almost all within their first two years. The infection in young children can cause lung damage that persists for years and may contribute to chronic lung disease in later life (chronic wheezing, asthma). Older children and adults often suffer from a (bad) common cold upon RSV infection. In old age, susceptibility again increases, and RSV has been implicated in a number of outbreaks of pneumonia in the aged resulting in significant mortality.
• ribavirin a nucleoside analogue that provides an aerosol treatment for serious RSV infection in hospitalized children.
• the other two drugs, RespiGam® (RSV-IG) and Synagis® (palivizumab), polyclonal and monoclonal antibody immunostimulants, are intended to be used in a preventive way. Both are very expensive, and require parenteral administration.
• a reference on benzimidazole antiviral agents is WO-01/95910.
• compounds are presented to have antiviral activity, yet with EC 50 values over a wide range of from 0.001 ⁇ m to as high as 50 ⁇ M (which does not normally represent the desired biological activity).
• Another reference, relating to substituted 2-methyl-benzimidazole RSV antiviral agents, in the same range of activities is WO-03/053344.
• Another related background reference on compounds in the same range of activities is WO-02/26228 regarding benzimidazolone antiviral agents.
• a reference on structure-activity relations, in respect of RSV inhibition, of 5-substituted benzimidazole compounds is Kuo-Long Yu et al., Bioorganic and Medicinal Chemistry Letters 14 (2004) 1133-1137, Kuo-Long Yu et al., Bioorganic and Medicinal Chemistry Letters 17 (2007) 895-901, and X.
• WO-2004/069256 discloses 2-cyanopyrrolopyrimidines as capthepsin K or S inhibitors useful in the treatment of various pain disorders.
• WO-2008/147697 discloses benzimidazole derivatives as chymase inhibitors.
• WO-2012/080446, WO-2012/080447, WO-2012/080449, WO-2012/080450 and WO-2012/080481 all filed on 16 Dec. 2011 and published on 21 Jun. 2012 disclose benzimidazole derivatives having antiviral activity against respiratory syncytial virus.
• the invention in one aspect, presents antiviral compounds represented by formula (I),
• Het is a heterocycle having formula (b), (c), (d) or (e)
• each X independently is C or N; provided that at least one X is N;
• the invention relates to the foregoing compounds for use in the treatment of RSV infections in warm-blooded animals, preferably humans.
• the invention presents a method of treatment of viral RSV infections in a subject in need thereof, comprising administering to said subject an effective amount of a compound as defined above.
• the invention resides in the use of a compound as defined above, for the manufacture of a medicament in the treatment of RSV infections.
• the invention relates to a pharmaceutical composition
• a pharmaceutical composition comprising a compound as defined above, and a pharmaceutically acceptable excipient.
• the invention provides methods for preparing the compounds defined above.
• the invention in a broad sense, is based on the judicious recognition that the compounds of Formula (I) generally possess an interesting RSV inhibitory activity. Moreover, these compounds enable access to anti-RSV activities at the higher regions (lower end of the EC 50 values) of the range available in the aforementioned references. Particularly, on the basis of these compounds, molecular structures can be uncovered that even outperform the reference compounds in terms of biological activities.
• substituted is used in the present invention, it is meant, unless otherwise is indicated or is clear from the context, to indicate that one or more hydrogens, in particular from 1 to 4 hydrogens, preferably from 1 to 3 hydrogens, more preferably 1 hydrogen, on the atom or radical indicated in the expression using “substituted” are replaced with a selection from the indicated group, provided that the normal valency is not exceeded, and that the substitution results in a chemically stable compound, i.e. a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into a therapeutic agent.
• C 1 -C 4 alkyl or “C 1-4 alkyl” as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as methyl, ethyl, propyl, 1-methylethyl, butyl and the like.
• C 1 -C 6 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as methyl, ethyl, propyl, 1-methylethyl, butyl, pentyl, hexyl, 2-methylbutyl and the like.
• C 1 -C 10 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 10 carbon atoms such as the groups defined for C 1 -C 6 alkyl and heptyl, octyl, nonyl, 2-methylhexyl, 2-methylheptyl, decyl, 2-methylnonyl, and the like.
• C 2 -C 10 alkenyl used herein as a group or part of a group is meant to comprise straight or branched chain unsaturated hydrocarbon radicals having at least one double bond, and preferably having one double bond, and from 2 to 10 carbon atoms such as ethenyl, propenyl, buten-1-yl, buten-2-yl, penten-1-yl, penten-2-yl, hexen-1-yl, hexen-2-yl, hexen-3-yl, 2-methylbuten-1-yl, hepten-1-yl, hepten-2-yl, hepten-3-yl, hepten-4-yl, 2-methylhexen-1-yl, octen-1-yl, octen-2-yl, octen-3-yl, octen-4-yl, 2-methylhepten-1-yl, nonen-1-yl, nonen-2-yl, nonen-3
• a “C 2 -C 10 alkenyl” group is linked to a heteroatom it preferably is linked via a saturated carbon atom.
• C 1 -C 4 alkyloxy or “C 1 -C 4 alkoxy”, as a group or part of a group defines an O—C 1 -C 4 alkyl radical, wherein C 1 -C 4 alkyl has, independently, the meaning given above.
• C 1 -C 6 alkyloxy or “C 1 -C 6 alkoxy”, as a group or part of a group defines an O—C 1 -C 6 alkyl radical, wherein C 1 -C 6 alkyl has, independently, the meaning given above.
• C 3 -C 7 cycloalkyl alone or in combination, refers to a cyclic saturated hydrocarbon radical having from 3 to 7 carbon atoms.
• suitable C 3 -C 7 cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
• —(CR 8 R 9 ) m — used herein defines m repetitions of the CR 8 R 9 subgroup, wherein each of these subgroups is independently defined.
• halo or “halogen” as a group or part of a group is generic for fluoro, chloro, bromo, iodo unless otherwise is indicated or is clear from the context.
• NRCOOR is identical to N(R)COOR.
• Examples of (but not limited to) a 4 to 6 membered aliphatic ring optionally containing one or more heteroatoms selected from the group consisting of N, S and O, as used in the definitions of R 8 and R 9 are cyclobutyl, cyclopentyl, cyclohexyl, piperidinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, azetidinyl, thiolanyl, piperazinyl, pyrrolidinyl.
• Het 2 is thiazolyl or quinolinyl.
• Het 1 is azetidinyl.
• radical positions on any molecular moiety used in the definitions may be anywhere on such moiety as long as it is chemically stable. Radicals used in the definitions of the variables include all possible isomers unless otherwise indicated. For instance pentyl includes 1-pentyl, 2-pentyl and 3-pentyl.
• each definition is independent.
• compound of formula (I) or “compounds of formula (I)” is meant to include the stereoisomeric forms thereof, and the pharmaceutically acceptable addition salts, and the solvates thereof.
• stereoisomers “stereoisomeric forms” or “stereochemically isomeric forms” hereinbefore or hereinafter are used interchangeably.
• stereochemically isomeric forms as used hereinbefore defines all the possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of formula (I) may possess.
• the invention includes all stereoisomers of the compound of Formula (I), either as a pure stereoisomer or as a mixture of two or more stereoisomers.
• Enantiomers are stereoisomers that are non-superimposable mirror images of each other.
• a 1:1 mixture of a pair of enantiomers is a racemate or racemic mixture.
• Diastereomers or diastereoisomers
• the substituents may be in the E or the Z configuration.
• Substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or trans-configuration; for example if a compound contains a disubstituted cycloalkyl group, the substituents may be in the cis or trans configuration. Therefore, the invention includes enantiomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof, whenever chemically possible.
• the absolute configuration is specified according to the Cahn-Ingold-Prelog system.
• the configuration at an asymmetric atom is specified by either R or S.
• Resolved compounds whose absolute configuration is not known can be designated by (+) or ( ⁇ ) depending on the direction in which they rotate plane polarized light.
• stereoisomer is substantially free, i.e. associated with less than 50%, preferably less than 20%, more preferably less than 10%, even more preferably less than 5%, in particular less than 2% and most preferably less than 1%, of the other isomers.
• a compound of formula (I) is for instance specified as (R)
• a compound of formula (I) is for instance specified as E
• E this means that the compound is substantially free of the Z isomer
• a compound of formula (I) is for instance specified as cis, this means that the compound is substantially free of the trans isomer.
• the chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the compounds of the present invention both in pure form or in admixture with each other are intended to be embraced within the scope of the present invention.
• Pure stereoisomeric forms of the compounds and intermediates of this invention may be obtained by the application of art-known procedures.
• enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids or bases. Examples thereof are tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid and camphosulfonic acid.
• enantiomers may be separated by chromatographic techniques using chiral stationary phases.
• Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.
• said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
• the diastereomeric racemates of formula (I) can be obtained separately by conventional methods.
• Appropriate physical separation methods that may advantageously be employed are, for example, selective crystallization and chromatography, e.g. column chromatography.
• the absolute stereochemical configuration was not experimentally determined.
• a person skilled in the art is able to determine the absolute configuration of such compounds using art-known methods such as, for example, X-ray diffraction.
• the present invention is also intended to include all isotopes of atoms occurring on the present compounds.
• Isotopes include those atoms having the same atomic number but different mass numbers.
• isotopes of hydrogen include tritium and deuterium.
• isotopes of carbon include C-13 and C-14.
• salts of the compounds of formula (I) are those wherein the counterion is pharmaceutically acceptable.
• salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
• the pharmaceutically acceptable acid and base addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid and base addition salt forms which the compounds of formula (I) are able to form.
• the pharmaceutically acceptable acid addition salts can conveniently be obtained by treating the base form with such appropriate acid.
• Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e.
• butanedioic acid maleic, fumaric, malic (i.e. hydroxybutanedioic acid), tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids.
• salt forms can be converted by treatment with an appropriate base into the free base form.
• the compounds of formula (I) containing an acidic proton may also be converted into their non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases.
• Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
• solvate comprises the hydrates and solvent addition forms which the compounds of Formula (I) are able to form, as well as the salts thereof. Examples of such forms are e.g. hydrates, alcoholates and the like.
• a compound according to the invention therefore inherently comprises a compound with one or more isotopes of one or more element, and mixtures thereof, including a radioactive compound, also called radiolabelled compound, wherein one or more non-radioactive atoms has been replaced by one of its radioactive isotopes.
• radiolabelled compound any compound according to Formula (I) which contains at least one radioactive atom.
• a compound can be labelled with positron or with gamma emitting radioactive isotopes.
• the 3 H-atom or the 125 I-atom is the atom of choice to be replaced.
• the most commonly used positron emitting (PET) radioactive isotopes are 11 C, 18 F, 15 O and 13 N, all of which are accelerator produced and have half-lives of 20, 100, 2 and 10 minutes (min) respectively. Since the half-lives of these radioactive isotopes are so short, it is only feasible to use them at institutions which have an accelerator on site for their production, thus limiting their use.
• the most widely used of these are 18 F, 99m Tc, 201 Tl and 123 I.
• the handling of these radioactive isotopes, their production, isolation and incorporation in a molecule are known to the skilled person.
• the radioactive atom is selected from the group of hydrogen, carbon, nitrogen, sulfur, oxygen and halogen.
• the radioactive isotope is selected from the group of 3 H, 11 C, 18 F, 122 I, 123 I, 125 I, 131 I, 75 Br, 76 Br, 77 Br and 82 Br.
• the present invention concerns novel compounds of Formula (I) and stereoisomeric forms thereof, wherein Het is a heterocycle having formula (b), (c), (d) or (e);
• the present invention concerns novel compounds of Formula (I) and stereoisomeric forms thereof, wherein Het is a heterocycle having formula (b), (c), (d) or (e);
• the present invention concerns novel compounds of Formula (I) and stereoisomeric forms thereof, wherein Het is a heterocycle having formula (b), (c), (d) or (e);
• the present invention concerns novel compounds of Formula (I) and stereoisomeric forms thereof, wherein Het is a heterocycle having formula (b), (c), (d) or (e);
• the present invention concerns novel compounds of Formula (I) and stereoisomeric forms thereof, wherein Het is a heterocycle having formula (b), (c), (d) or (e);
• the present invention concerns novel compounds of Formula (I) and stereoisomeric forms thereof, wherein Het is a heterocycle having formula (b), (c), (d) or (e);
• the present invention concerns novel compounds of Formula (I) and stereoisomeric forms thereof, wherein Het is a heterocycle having formula (b), (c), (d) or (e);
• the present invention concerns novel compounds of Formula (I) and stereoisomeric forms thereof, wherein Het is a heterocycle having formula (b), (c), (d) or (e);
• the present invention concerns novel compounds of Formula (I) and stereoisomeric forms thereof, wherein Het is a heterocycle having formula (b), (c), (d) or (e); in particular (b) or (c);
• the present invention concerns novel compounds of Formula (I) and stereoisomeric forms thereof, wherein Het is a heterocycle having formula (b), (c), (d) or (e); in particular (b) or (c);
• the present invention concerns novel compounds of Formula (I) and stereoisomeric forms thereof, wherein Het is a heterocycle having formula (b), (c), (d) or (e);
• the present invention concerns novel compounds of Formula (I) and stereoisomeric forms thereof, wherein
• the present invention concerns novel compounds of Formula (I) and stereoisomeric forms thereof,
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein each R 8 and R 9 are independently chosen from the group consisting of H, C 1 -C 10 alkyl and C 3 -C 7 cycloalkyl.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 4 is Het 1 .
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 4 is aryl or Het 2 ; in particular Het 2 .
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments,
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein
• the present invention concerns novel compounds of Formula (I) and stereoisomeric forms thereof, wherein
• the present invention concerns novel compounds of Formula (I) and stereoisomeric forms thereof, wherein
• the present invention concerns novel compounds of Formula (I) and stereoisomeric forms thereof, wherein
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 4 is selected from the group consisting of Het 1 and C 3 -C 7 cycloalkyl substituted with one or more substituents selected from the group consisting of halo and C 1 -C 4 alkyl; in particular R 4 is Het1.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein SO 2 R 8 is restricted to SO 2 CH 3 or SO 2 C 3 -C 7 cycloalkyl; in particular SO 2 CH 3 .
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 4 is selected from the group consisting of Het 1 , aryl, Het 2 , and C 3 -C 7 cycloalkyl substituted with one or more substituents selected from the group consisting of halo and C 1 -C 4 alkyl; in particular Het 1 , Het 2 , and C 3 -C 7 cycloalkyl substituted with one or more substituents selected from the group consisting of halo and C 1 -C 4 alkyl.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 4 is selected from the group consisting of Het 1 and C 3 -C 7 cycloalkyl substituted with one or more substituents selected from the group consisting of halo and C 1 -C 4 alkyl; in particular R 4 is Het1; and wherein
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 4 is Het 1 , and wherein
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 4 is Het 1 , and wherein
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 4 is Het 1 , and wherein
• the present invention concerns novel compounds of Formula (I) and stereoisomeric forms thereof, wherein
• C 1 -C 10 alkyl in particular H and C 1 -C 6 alkyl;
• the present invention concerns novel compounds of Formula (I) and stereoisomeric forms thereof, wherein
• the present invention concerns novel compounds of Formula (I) and stereoisomeric forms thereof, wherein
• the present invention concerns novel compounds of Formula (I) and stereoisomeric forms thereof, wherein
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 5 is selected from the group consisting of CF 3 and halogen.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 3e is —(CR 8 R 9 ) m —R 10e .
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (b) or (c).
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (b).
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (c).
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (d).
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (e).
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het is a heterocycle having formula (bb), (cc), (dd) or (ee); in particular (bb) or (cc); more in particular (bb); more in particular (cc); more in particular (dd); more in particular (cc);
• R 1bb , R 1cc , R1 dd or R 1ee are chloro or bromo; in particular chloro; wherein R 1b , R 1c , R1 d , R 1e and the other substituents are defined according to any of the other embodiments; in a particular embodiment R 1bb , R 1cc , R1 dd or R 1ee are chloro; R 1b , R 1c , R1 d , R 1e if present are H; and the other substituents are defined according to any of the other embodiments.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het is a heterocycle having formula (b-1) or (c ⁇ 1); in particular (b ⁇ 1); also in particular (c ⁇ 1);
• R 1b and R 1c are chloro or bromo.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het is a heterocycle having formula (b-1a) or (c-1a); in particular (b-1a); also in particular (c-1a);
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein
• R 4 is selected from the group consisting of tert-butyl, azetidinyl substituted on the N atom with one substituent selected from the group consisting of C 1 -C 4 alkylcarbonyl and C 1 -C 4 alkyloxycarbonyl, phenyl substituted with one substituent selected from the group consisting of F and C 1 -C 4 alkyloxy, and cyclopropyl substituted with one substituent selected from the group consisting of C 1 -C 4 alkyl and F;
• Z is C or N;
• R 5 is present where Z is C, whereby R 5 is halogen;
• R 5 is absent where Z is N.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 4 is selected from the group consisting of tert-butyl, Het 1 , aryl, Het 2 and C 3 -C 7 cycloalkyl substituted with one or more substituents selected from the group consisting of halo and C 1 -C 4 alkyl.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 4 is selected from the group consisting of tert-butyl, Het 1 , CH(CH 3 )(CF 3 ), and C 3 -C 7 cycloalkyl substituted with one or more substituents selected from the group consisting of halo and C 1 -C 4 alkyl; in particular R 4 is selected from the group consisting of Het 1 and C 3 -C 7 cycloalkyl substituted with one or more substituents selected from the group consisting of halo and C 1 -C 4 alkyl; more in particular R 4 is Het 1 .
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 4 is selected from the group consisting of tert-butyl, aryl, Het 2 and CH(CH 3 )(CF 3 ); in particular R 4 is aryl or Het 2 ; more in particular R 4 is Het 2 .
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Z is C or N; R 5 is present where Z is C, whereby R 5 is selected form the group consisting of CF 3 and halogen; R 5 is absent where Z is N.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein each R 1c is selected independently from the group consisting of H, halogen, C 1 -C 6 alkyloxy, CF 3 , and OCF 3 .
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (c) wherein each R 1c is selected independently from the group consisting of H, halogen, C 1 -C 6 alkyloxy, CF 3 , and OCF 3 .
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 1c in the para position to N—R 2 ° is selected from the group consisting of H, halogen and all other R 1c are H.
• halogen is bromo or chloro.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (c) wherein R 1c in the para position to N—R 2 ° is selected from the group consisting of H, halogen and all other R 1c are H.
• halogen is bromo or chloro.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (c) wherein R 2c comprises a —(CR 8 R 9 ) m chain wherein R 8 and R 9 are H and m is 2-4.
• R 10c is selected from the group consisting of OH, F, CF 2 H, CF 3 , SO 2 R 8 , and CN.
• R 8 preferably is methyl.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 2c comprises a —(CR 8 R 9 ) chain wherein R 8 and R 9 are H and m is 2-4.
• R 10c is selected from the group consisting of OH, F, CF 2 H, CF 3 , SO 2 R 8 , and CN.
• R 8 preferably is methyl.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 4 is C 3 -C 7 cycloalkyl substituted with one or more substituents selected from the group consisting of halo and C 1 -C 4 alkyl; more preferably cyclopropyl substituted with halo or C 1 -C 4 alkyl.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Z is N.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 5 is H.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 4 is selected from the group consisting of tert-butyl, Het 1 , aryl, Het 2 and C 3 -C 7 cycloalkyl substituted with one or more substituents selected from the group consisting of halo and C 1 -C 4 alkyl;
• R 10b is selected from the group consisting of H, C 1 -C 6 alkyl, OH, CN, F, CF 2 H, CF 3 , CONR 8 R 9 , COOR 8 , CON(R 8 )SO 2 R 9 , CON(R 8 )SO 2 N(R 8 R 9 ), NR 8 R 9 , NR 8 COOR 9 , OCOR 8 , O-Benzyl, NR 8 SO 2 R 9 , SO 2 NR 8 R 9 , SO 2 R 8 and a 4 to 6 membered saturated ring containing one oxygen atom; and m is an integer from 2 to 6.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 10b is selected from the group consisting of H, C 1 -C 6 alkyl, OH, CN, F, CF 2 H, CF 3 , CONR 8 R 9 , COOR 8 , CON(R 8 )SO 2 R 9 , CON(R 8 )SO 2 N(R 8 R 9 ), NR 8 R 9 , NR 8 COOR 9 , OCOR 8 , O-Benzyl, NR 8 SO 2 R 9 , SO 2 NR 8 R 9 , SO 2 R 8 and a 4 to 6 membered saturated ring containing one oxygen atom.
• R 10b is selected from the group consisting of H, C 1 -C 6 alkyl, OH, CN, F, CF 2 H, CF 3 , CONR 8 R 9 , COOR 8 , CON(R 8 )SO 2 R 9 , CON(R 8 )SO 2
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (b) wherein R 10b is selected from the group consisting of H, C 1 -C 6 alkyl, OH, CN, F, CF 2 H, CF 3 , CONR 8 R 9 , COOR 8 , CON(R 8 )SO 2 R 9 , CON(R 8 )SO 2 N(R 8 R 9 ), NR 8 R 9 , NR 8 COOR 9 , OCOR 8 , O-Benzyl, NR 8 SO 2 R 9 , SO 2 NR 8 R 9 , SO 2 R 8 and a 4 to 6 membered saturated ring containing one oxygen atom.
• R 10b is selected from the group consisting of H, C 1 -C 6 alkyl, OH, CN, F, CF 2 H, CF 3 , CONR 8 R 9 , COOR 8 , CON(R 8 )SO 2 R 9
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (b) wherein at most two X are N.
• one X is N.
• the one X that is N is located in meta position to the N—R 2b group of the imidazole ring.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het having formula (b) has at most two X being N.
• one X is N.
• the one X that is N is located in meta position to the N—R 2b group of the imidazole ring.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein each R 1b is selected independently from the group consisting of H, halogen and CH 2 —NH 2 .
• R 1b in the para position to C—N—R 2b is selected from the group consisting of H, halogen and CH 2 —NH 2 , and all other R 1b are H.
• said halogen is bromo or chloro.
• at most one R 1b is chloro, and all other R 1b are H.
• R 1b in the para position to C—N—R 2b is chloro.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (b) wherein each R 1b is selected independently from the group consisting of H, halogen and CH 2 —NH 2 .
• R 1b in the para position to C—N—R 2b is selected from the group consisting of H, halogen and CH 2 —NH 2 , and all other R 1b are H.
• said halogen is bromo or chloro.
• at most one R 1b is chloro, and all other R 1b are H.
• R 1b in the para position to C—N—R 2b is chloro.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 11 is C 1 -C 6 alkyl or C 3 -C 7 cycloalkyl; in particular C 1 -C 6 alkyl.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 2b comprises a —(CR 8 R 9 ) m —R 10b chain wherein R 8 and R 9 are preferably H and m is 2-4.
• R 10b is selected from the group consisting of OH, C 1 -C 6 alkyl; more preferably 2-propyl.
• R 10b is selected from the group consisting of methoxy, SO 2 R 8 , with R 8 preferably being methyl.
• R 10b is fluoro or CF 3 .
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (b) wherein R 2b comprises a —(CR 8 R 9 ) m —R 10b chain wherein R 8 and R 9 are preferably H and m is 2-4.
• R 10b is selected from the group consisting of OH, C 1 -C 6 alkyl; more preferably 2-propyl.
• R 10b is selected from the group consisting of methoxy, SO 2 R 8 , with R 8 preferably being methyl.
• R 10b is fluoro or CF 3 .
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 4 is selected from C 3 -C 7 cycloalkyl substituted with one or more substituents selected from the group consisting of halo and C 1 -C 4 alkyl.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 4 is selected from the group consisting of Het 1 and cyclopropyl substituted with halo or C 1 -C 4 alkyl.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 5 is halogen, in particular fluoro.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein each R 1d independently is selected from the group of H, halogen, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, C 1 -C 6 alkyloxy, N(R 6 ) 2 , CO(R 6 ), CH 2 NH 2 , CH 2 OH, CN, C( ⁇ NOH)NH 2 , C( ⁇ NOCH 3 )NH 2 , C( ⁇ NH)NH 2 , CF 3 , OCF 3 , B(OH) 2 and B(O—C 1 -C 6 alkyl) 2 .
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (d) wherein each R 1d independently is selected from the group of H, halogen, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, C 1 -C 6 alkyloxy, N(R 6 ) 2 , CO(R 6 ), CH 2 NH 2 , CH 2 OH, CN, C( ⁇ NOH)NH 2 , C( ⁇ NOCH 3 )NH 2 , C( ⁇ NH)NH 2 , CF 3 , OCF 3 , B(OH) 2 and B(O—C 1 -C 6 alkyl) 2 .
• each R 1d independently is selected from the group of H, halogen, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, C 1 -C 6 alkyloxy, N(R 6 ) 2 , CO(R 6 ), CH 2
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (d) wherein at most two X are N.
• one X is N.
• the one X that is N is located is in meta or para position to the N—R 2d .
• X is in the position para to N—R 2d .
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het having formula (d) has at most two X being N.
• one X is N.
• the one X that is N is located is in meta or para position to the N—R 2d .
• X is in the position para to N—R 2d .
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein each R 1d is selected independently from the group consisting of H or halogen.
• R 1d in the para position to N—R 2d is halogen, and all other R 1d are H.
• said halogen is bromo or chloro. In a most preferred embodiment, said halogen is chloro.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (d) wherein each R 1d is selected independently from the group consisting of H or halogen.
• R 1d in the para position to N—R 2d is halogen, and all other R 1d are H.
• said halogen is bromo or chloro. In a most preferred embodiment, said halogen is chloro.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 2d comprises a —(CR 8 R 9 ) chain wherein R 8 and R 9 are preferably H and m is 2-4.
• R 10d is selected from the group consisting of OH, F, CF 3 , CF 2 H and C 1 -C 6 alkyl; in particular 2-propyl.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (d) wherein R 2d comprises a —(CR 8 R 9 ) m chain wherein R 8 and R 9 are preferably H and m is 2-4.
• R 10d is selected from the group consisting of OH, F, CF 3 , CF 2 H and C 1 -C 6 alkyl; in particular 2-propyl.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (e) wherein R 3e is selected from the group consisting of H, halogen, —(CR 8 R 9 ) m —R 10e , C ⁇ C—CH 2 —R 10e and C ⁇ C—R 10e .
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 3e is selected from the group consisting of H, halogen, —(CR 8 R 9 ) m —R 10e , C ⁇ C—CH 2 —R 10e and C ⁇ C—R 10e .
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (e) wherein Y is C.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Y is C.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het having formula (e) is limited to formula (e1)
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein all substituents R 1e are H.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (e) wherein all substituents R 1e are H.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein at least one of R 1e is halogen, more preferably Cl or Br.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (e) wherein at least one of R 1e is halogen, more preferably Cl or Br.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein m comprises a carbon chain of 2-6 atoms, in particular 2-4 atoms, more in particular 3-5 atoms.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 10e is selected from the group consisting of OH, C 1 -C 6 alkyloxy, secondary C 1 -C 6 alkyl; in particular OH or 2-propyl.
• R 10e is selected from the group consisting of OH, C 1 -C 6 alkyloxy, secondary C 1 -C 6 alkyl; in particular OH or 2-propyl.
• “Secondary C 1 -C 6 alkyl” is intended to refer to an alkyl moiety that is attached via a non-terminal carbon atom, e.g. 2-propyl, 3-pentyl, and the like.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (e) wherein R 10e is selected from the group consisting of OH, C 1 -C 6 alkyloxy, secondary C 1 -C 6 alkyl; in particular OH or 2-propyl.
• R 10e is selected from the group consisting of OH, C 1 -C 6 alkyloxy, secondary C 1 -C 6 alkyl; in particular OH or 2-propyl.
• “Secondary C 1 -C 6 alkyl” is intended to refer to an alkyl moiety that is attached via a non-terminal carbon atom, e.g. 2-propyl, 3-pentyl, and the like.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein R 3e is C ⁇ C—CH 2 —R 10e .
• R 10e preferably is C 1 -C 6 alkyloxy, preferably methoxy, or C 1 -C 6 alkyl, preferably branched alkyl.
• the present invention relates to those compounds of formula (I), or any subgroup thereof as mentioned in any of the other embodiments, wherein Het has formula (e) wherein R 3e is C ⁇ C—CH 2 —R 10e .
• R 10e preferably is C 1 -C 6 alkyloxy, preferably methoxy, or C 1 -C 6 alkyl, preferably branched alkyl.
• the compounds of formula I may be prepared by the methods described below, using synthetic methods known in the art of organic chemistry, or modifications and derivatisations that are familiar to those skilled in the art.
• the starting materials used herein are commercially available or may be prepared by routine methods known in the art such as those methods disclosed in standard reference books. Preferred methods include, but are not limited to, those described below.
• Scheme 1 illustrates a method for the preparation of compounds of formula (I), wherein Het is a heterocycle of formula (b), hereby named a compound of formula I-b where R 1b , R 2b , R 4 , R 5 and Z are defined as above.
• a compound of formula I-b can be synthesized by coupling 2-hydroxymethylene imidazopyridines of formula II-a with a N 3 -substituted 2-oxo-imidazopyridine or with a N 3 -substituted 2-oxo-imidazobenzene of formula III in a known in the art method such as a Mitsunobu reaction which uses azadiisopropyldicarboxylate and triphenyl phosphine in a suitable solvent such as DMF (N,N-dimethylformamide) or THF (tetrahydrofuran).
• a Mitsunobu reaction which uses azadiisopropyldicarboxylate and triphenyl phosphine in a suitable solvent such as DMF (N,N-dimethylformamide) or THF (tetrahydrofuran).
• a compound of formula I-b may be prepared by displacement of Q, which is a halide, preferably chlorine II-b, or a sulfonate such as mesylate II-c in the presence of a base such as sodium hydride, potassium carbonate or cesium carbonate in a suitable solvent such as DMF or THF.
• Q which is a halide, preferably chlorine II-b, or a sulfonate such as mesylate II-c in the presence of a base such as sodium hydride, potassium carbonate or cesium carbonate in a suitable solvent such as DMF or THF.
• alcohol II-a Treatment of the alcohol II-a with thionyl chloride provides 2-chloromethyl imidazopyridines II-b.
• alcohol II-a may be transformed to the intermediate II-c by a reaction with methane sulfonyl chloride in the presence of an organic base such as triethyl amine or diisopropyl ethyl amine in a suitable solvent such as dichloromethane (scheme 2).
• Hydrogenation of the nitro group using well-precedented conditions such as Pd/C, or other catalyst, under hydrogen or Fe/EtOH/CaCl 2 can yield diamine of formula VII-b.
• the hydrogenation of the nitro group of intermediate VIII-b using well-precedented conditions such as Pd/C, or other catalyst, under hydrogen or Fe/EtOH/CaCl 2 yield diamine of formula IX-b which can be treated with the aldehydes of formula X-b in the presence of suitable reducing agents such as NaBH(OAc) 3 (sodium triacetoxyborohydride), or Na(CN)BH 3 in solvents such as methylene chloride, DMF or THF, at about room temperature gives compounds of formula VII-b.
• suitable reducing agents such as NaBH(OAc) 3 (sodium triacetoxyborohydride), or Na(CN)BH 3 in solvents such as methylene chloride, DMF or THF
• the imidazole ring can be formed by treating diamines VII-b with glycolic acid or an ester like XIII-b under strong acidic conditions, such as aqueous hydrochloric acid, at elevated temperature such as reflux to yield the alcohols of formula II-a.
• diamines VII-b can be condensed with dialkoxyacetate of formula XII-b, in the presence of acetic acid, in a suitable solvent such as methanol gives the acetal II-e.
• the acetal of compounds II-e can be removed with acids such as hydrochloric acid to give the aldehydes of formula II-f.
• the resulting aldehydes of formula II-f can be reduced to alcohols using a suitable reducing agent such as NaBH 4 or LiA1H 4 in a suitable solvent such as ethanol or THF to yield the desired alcohols of formula II-a.
• diamines VII-b can be cyclize with dialkyl oxalate of formula XI-b in a suitable solvent such as ethanol at elevated temperature with or without microwave heating to produce imidazoles of formula II-d.
• intermediates of formula II-d may be prepared in two steps synthesis starting from diamines VII-b.
• diamine VII-b may be reacted with an alkyl trihaloacetimidate, preferably methyl 2,2,2-trichloro-acetimidate, in an acidic media, preferably acetic acid, at a temperature ranging between 25 and 50° C. to yield compound of formula II-g.
• an alkyl trihaloacetimidate preferably methyl 2,2,2-trichloro-acetimidate
• an acidic media preferably acetic acid
• Diamine IX-b may be first coupled to an alkyl glycolic acid or an ester like XIII-b under strong acidic conditions, such as aqueous hydrochloric acid, at elevated temperature such as reflux to yield the alcohols of formula XIV-b.
• This alcohol may be protected by a PG, where PG is a protecting group such as, but not limiting to, a trityl which consequently results in intermediates of formula XV-b.
• a suitable solvent for this type of reactions can be, but not limiting to, dichloromethane.
• intermediate II-h The treatment of intermediate XV-b with intermediate XVI-b, wherein the LG is a leaving group, such as halide, preferably bromine, or sulfonate, in the presence of a base such as sodium hydride, potassium carbonate or cesium carbonate in a suitable solvent such as DMF or THF, gives intermediate II-h.
• a base such as sodium hydride, potassium carbonate or cesium carbonate in a suitable solvent such as DMF or THF
• the removal of the PG in intermediate II-h may be done in the presence of an acid such as hydrochloric acid in the presence of a solvent, not limited to, such as dioxane to yield an intermediate of formula II-a.
• Reduction of the nitro group to the amine XIX can be done in a catalytic way using hydrogen in the presence of a catalyst such as palladium or platinum, in a suitable solvent such as methanol, or in a stoichiometric way using iron in the presence of ammonium chloride or tin chloride in the presence of concentrated hydrochloric acid.
• a catalyst such as palladium or platinum
• a suitable solvent such as methanol
• R 4 substituent other than H
• Introduction of a R 4 substituent (other than H) on an intermediate of formula XXI can be accomplished by a Mitsunobu reaction with commercially available alcohols, or by displacement of the LG in the intermediates of formula XXII, where LG is a leaving group such as halide, preferably bromine, or sulfonate, in the presence of a base such as sodium hydride, potassium carbonate or cesium carbonate in a suitable solvent such as DMF or THF.
• a base such as sodium hydride, potassium carbonate or cesium carbonate
• Scheme 6 illustrates a method for the preparation of compounds of formula (I), wherein Het is a heterocycle of formula (c), hereby named a compound of formula I-c, where R 1c , R 2c , R 3c , R 4 , R 5 and Z are defined as above.
• a compound of formula I-c can be synthesized by coupling a 2-hydroxymethylene indole of formula II-i with a N 3 -substituted 2-oxo-imidazopyridine or with a N 3 -substituted 2-oxo-imidazobenzene of formula III with a method known in the art method such as a Mitsunobu reaction which uses azadiisopropyldicarboxylate and triphenyl phosphine in a suitable solvent such as DMF or THF.
• a compound of formula I-c may be prepared by displacement of Y, which is a halide, preferably chlorine II-j, or a sulfonate such as mesylate II-k in the presence of a base such as sodium hydride, potassium carbonate or cesium carbonate in a suitable solvent such as DMF or THF.
• Y is a halide, preferably chlorine II-j, or a sulfonate such as mesylate II-k in the presence of a base such as sodium hydride, potassium carbonate or cesium carbonate in a suitable solvent such as DMF or THF.
• Starting materials IV-c used in this invention are commercially available, or can be synthesized, but not limited to, by methods known in the art such as Reissert synthesis or Fischer synthesis.
• Reaction of such indoles with R 2c -LG, where LG is a leaving group such as halide, preferably bromine, or sulfonate, in the presence of a base such as sodium hydride, potassium carbonate or cesium carbonate in a suitable solvent such as DMF or THF gives intermediates V-c (scheme 7).
• the conversion of the alkyl ester of an intermediate of formula V-c to the alcohol II-i may be carried out with metal hydride such as lithium aluminum hydride or sodium borohydride in a suitable solvent such as THF, methanol or ethanol.
• starting materials VI-c can be synthesized, but not limited to, by methods known in the art such as Reissert synthesis or Fischer synthesis.
• Reaction of such indoles with R 2c -LG, where LG is a leaving group such as halide, preferably bromine, or sulfonate, in the presence of a base such as sodium hydride, potassium carbonate or cesium carbonate in a suitable solvent such as DMF or THF gives intermediates of formula VII-c.
• the oxidation of the methyl with selenium oxide or manganese dioxide in a suitable solvent such as dichloromethane or heptane leads to the aldehyde VIII-c.
• the conversion of the aldehyde VIII-c to the alcohol II-i may be carried out with metal hydride such as lithium aluminum hydride or sodium borohydride in a suitable solvent such as THF, methanol or ethanol.
• alcohol II-i Treatment of the alcohol II-i with thionyl chloride provides 2-chloromethyl indole II-j.
• alcohol II-i may be transformed to the intermediate II-k by a reaction with methane sulfonyl chloride in the presence of an organic base such as triethyl amine or diisopropyl ethyl amine in a suitable solvent such dichloromethane (scheme 8).
• Scheme 9 illustrates a method for the preparation of compounds of formula I-d, where R 1d , R 2d , R 3d , R 4 , R 5 and Z are defined as above.
• a compound of formula I-d can be synthesized by coupling 2-hydroxymethylene indole II-l with a benzimidazolone III in a known in the art method such as Mitsunobu reaction which uses azadiisopropyldicarboxylate (DIAD) and triphenylphosphine in a suitable solvent such as DMF or THF.
• compounds of formula I-d may be prepared by displacement of Q, which is a halide, preferably chlorine II-m, or sulfonate such as mesylate II-n in the presence of a base such as, but not limiting to, sodium hydride, potassium carbonate or cesium carbonate in a suitable solvent such as DMF or THF.
• Starting materials IV-d used in this invention are commercially available, or can be synthesized, but not limited to, by methods known in the art such as Reissert synthesis or Fischer synthesis.
• Reaction of such an intermediate with R 2d -LG, where LG is a leaving group such as halide, preferably bromine, or sulfonate, in the presence of a base such as sodium hydride, potassium carbonate or cesium carbonate in a suitable solvent such as DMF or THF gives an intermediate of formula V-d.
• the conversion of the alkyl ester of intermediate V-d to the alcohol II-l can be done with a metal hydride such as lithium aluminum hydride or sodium borohydride in a suitable solvent such as THF or methanol.
• a II-l type intermediate can also be synthesized as shown in scheme 10, method 2.
• the commercially available starting material VI-d is protected by a PG, where PG is a protecting group such as, but not limiting to, a tosyl, which consequently results in an intermediate of formula VII-d.
• a suitable solvent for this kind of reactions can be, but not limiting to, toluene.
• the esterification of acid in the intermediate IX-d can be performed with alcohols such methanol or ethanol in acidic conditions to yield intermediate X-d.
• the removal of the PG in intermediate X-d may be done in the presence of a base such as potassium carbonate or cesium carbonate in a suitable solvent such as THF and methanol to obtain indole XI-d.
• a base such as potassium carbonate or cesium carbonate in a suitable solvent such as THF and methanol
• the conversion of the alkyl ester of intermediate XII-d to the alcohol II-l can be carried out with a metal hydride such as lithium aluminium hydride or sodium borohydride in a suitable solvent such as THF or ethanol.
• Scheme 12 illustrates a method for the preparation of compounds of formula I-e, where R 1e , R 3e , R 4 , R 5 , R 10e , Q, Y and Z are defined as above.
• a IV-e type compound can be made by coupling 2-hydroxymethylene imidazopyridine II-o with a N 3 -substituted benzimidazolone III in a known in the art method such as Mitsunobu reaction which use the azadiisopropyldicarboxylate and triphenylphosphine in a suitable solvent such as, but not limiting to, DMF or THF.
• compounds of formula I-e may be prepared by displacement of Q, which is a halide, II-p, preferably chlorine, or sulfonate, II-q, such as mesylate or tosylate, in the presence of base such as, but not limiting to, sodium hydride, potassium carbonate or cesium carbonate in a suitable solvent such as DMF or THF.
• base such as, but not limiting to, sodium hydride, potassium carbonate or cesium carbonate
• a suitable solvent such as DMF or THF.
• Halogenating reagents such as, but not limited to, N-iodosuccinimide can be used to convert a IV-e type intermediate to a V-e type intermediate and CH 3 CN can be a suitable solvent for this reaction.
• a VI-e type intermediate By coupling an alkyn to a V-e type intermediate in a known in the art method such as Sonogashira-type coupling reaction, a VI-e type intermediate can be generated. Reduction of the triple bond can be done in a catalytic way using hydrogen in the presence of the catalyst such as palladium or platinum, in a suitable solvent such as methanol, or in a stoichiometric way using iron in the presence of ammoniumchloride or tin chloride in the presence of concentrated hydrochloric acid to yield a compound of formula I-e.
• the catalyst such as palladium or platinum
• a suitable solvent such as methanol
• IX-e type intermediate can be synthesized by coupling a commercially available VII-e type intermediate with a commercially available VIII-e type intermediate, of which the halogen is preferably bromine, through a base mediated coupling reaction.
• Possible bases to effect this reaction but not limiting to, are K 2 CO 3 , Cs 2 CO 3 , triethylamine and sodium hydride.
• a suitable solvent for this type of base mediated coupling is DME (1,2-dimethoxyethane).
• DME 1,2-dimethoxyethane
• Scheme 14 shows the possibilities to synthesize II-p and II-q type intermediates.
• Treatment of the alcohol II-o with reagents like, but not limiting to, SOCl 2 , PBr 3 , p-TsCl (4-toluenesulfonyl chloride), MsCl (methane sulfonyl chloride) provides 2-chloromethyl indole II-p and to the intermediate II-q in the presence of an organic base, such as triethylamine or diisopropylethylamine in a suitable solvent such as dichloromethane. This is illustrated by method 1.
• a II-p type compound can also be generated through an inter molecular ring closure between a commercially available XI-e type compound and an also commercially available XII-e type compound.
• a suitable solvent for this reaction can be ethanol. This is illustrated by method 2.
• Diastereomers may be separated by physical methods such as selective crystallization and chromatographic techniques, e.g., counter-current distribution, liquid chromatography and the like.
• the compounds of formula (I) as prepared in the hereinabove described processes are generally racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures.
• the racemic compounds of formula (I) which are sufficiently basic or acidic may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid, respectively chiral base. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali or acid.
• An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase.
• Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.
• said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomeric ally pure starting materials.
• the present invention concerns a pharmaceutical composition
• a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) as specified herein, or a compound of any of the embodiments of compounds of formula (I) as specified herein, and a pharmaceutically acceptable carrier.
• a therapeutically effective amount in this context is an amount sufficient to prophylaxictically act against, to stabilize or to reduce viral infection, and in particular RSV viral infection, in infected subjects or subjects being at risk of being infected.
• this invention relates to a process of preparing a pharmaceutical composition as specified herein, which comprises intimately mixing a pharmaceutically acceptable carrier with a therapeutically effective amount of a compound of formula (I), as specified herein, or of a compound of any of the embodiments of compounds of formula (I) as specified herein.
• compositions of the present invention may be formulated into various pharmaceutical forms for administration purposes.
• compositions there may be cited all compositions usually employed for systemically administering drugs.
• an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
• a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
• These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection.
• any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed.
• the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
• Injectable solutions may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
• Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations.
• the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin.
• the compounds of the present invention may also be administered via oral inhalation or insufflation by means of methods and formulations employed in the art for administration via this way.
• the compounds of the present invention may be administered to the lungs in the form of a solution, a suspension or a dry powder, a solution being preferred. Any system developed for the delivery of solutions, suspensions or dry powders via oral inhalation or insufflation are suitable for the administration of the present compounds.
• the present invention also provides a pharmaceutical composition adapted for administration by inhalation or insufflation through the mouth comprising a compound of formula (I) and a pharmaceutically acceptable carrier.
• a pharmaceutical composition adapted for administration by inhalation or insufflation through the mouth comprising a compound of formula (I) and a pharmaceutically acceptable carrier.
• the compounds of the present invention are administered via inhalation of a solution in nebulized or aerosolized doses.
• Unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
• unit dosage forms are tablets (including scored or coated tablets), capsules, pills, suppositories, powder packets, wafers, injectable solutions or suspensions and the like, and segregated multiples thereof.
• the compounds of formula (I) show antiviral properties.
• Viral infections treatable using the compounds and methods of the present invention include those infections brought on by ortho- and paramyxoviruses and in particular by human and bovine respiratory syncytial virus (RSV).
• RSV human and bovine respiratory syncytial virus
• a number of the compounds of this invention moreover are active against mutated strains of RSV.
• many of the compounds of this invention show a favorable pharmacokinetic profile and have attractive properties in terms of bioavailabilty, including an acceptable half-life, AUC and peak values and lacking unfavourable phenomena such as insufficient quick onset and tissue retention.
• the in vitro antiviral activity against RSV of the present compounds was tested in a test as described in the experimental part of the description, and may also be demonstrated in a virus yield reduction assay.
• the in vivo antiviral activity against RSV of the present compounds may be demonstrated in a test model using cotton rats as described in Wyde et al. (Antiviral Research (1998), 38, 31-42).
• the compounds of the present invention or any embodiment thereof may therefore be used as medicines.
• Said use as a medicine or method of treatment comprises the systemic administration to viral infected subjects or to subjects susceptible to viral infections of an amount effective to combat the conditions associated with the viral infection, in particular the RSV infection.
• the present invention also relates to the use of the present compounds or any embodiment thereof in the manufacture of a medicament for the treatment or the prevention of viral infections, particularly RSV infection.
• the present invention furthermore relates to a method of treating a warm-blooded animal infected by a virus, or being at risk of infection by a virus, in particular by RSV, said method comprising the administration of an anti-virally effective amount of a compound of formula (I), as specified herein, or of a compound of any of the embodiments of compounds of formula (I), as specified herein.
• an antivirally effective daily amount would be from 0.01 mg/kg to 500 mg/kg body weight, more preferably from 0.1 mg/kg to 50 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 1 to 1000 mg, and in particular 5 to 200 mg of active ingredient per unit dosage form.
• the exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that said effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective daily amount ranges mentioned hereinabove are therefore only guidelines.
• the combination of another antiviral agent and a compound of formula (I) can be used as a medicine.
• the present invention also relates to a product containing (a) a compound of formula (I), and (b) another antiviral compound, as a combined preparation for simultaneous, separate or sequential use in antiviral treatment.
• the different drugs may be combined in a single preparation together with pharmaceutically acceptable carriers.
• the compounds of the present invention may be combined with interferon-beta or tumor necrosis factor-alpha in order to treat or prevent RSV infections.
• eq. means equivalent, ‘THF’ means tetrahydrofuran, ‘Psi’ means pound-force per square inch, ‘DMF’ means N,N-dimethylformamide, ‘DMSO’ means dimethyl sulfoxide, ‘DIEA’ means diisopropylethylamine, ‘DIAD’ means diisopropyl azodicarboxylate, ‘HOAc’ or ‘AcOH’ means acetic acid, ‘RP’ means reversed phase, ‘EtOAc’ means ethyl acetate, ‘Pd(dppf)Cl 2 CH 2 Cl 2 ’ means [1,1′-bis(diphenylphosphino)ferrocene]palladium chloride complex with dichloromethane, ‘TPP’ means triphenylphosphine, ‘m-cPBA’ means 3-chlorobenzene-carboperoxoic acid, ‘Cu(OAc) 2 ’ means copper(II) a
• the LC measurement was performed using an Acquity UPLC (Waters) (′UPLC′ means Ultra Performance Liquid Chromatography) system comprising a binary pump, a sample organizer, a column heater (set at 55° C.), a diode-array detector (DAD) and a column as specified in the respective methods below.
• Flow from the column was split to a MS spectrometer.
• the MS detector was configured with an electrospray ionization source. Mass spectra were acquired by scanning from 100 to 1000 in 0.18 seconds using a dwell time of 0.02 seconds.
• the capillary needle voltage was 3.5 kV and the source temperature was maintained at 140° C. Nitrogen was used as the nebulizer gas.
• Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.
• the LC measurement was performed using an Acquity UPLC (Waters) system comprising a binary pump, a sample organizer, a column heater (set at 55° C.), a diode-array detector (DAD) and a column as specified in the respective methods below. All the flow from the column went to a MS spectrometer.
• the MS detector was configured with an electrospray ionization source. Mass spectra were acquired by scanning from 120 to 1000 in 0.1 seconds. The capillary needle voltage was 3.0 kV and the source temperature was maintained at 150° C. Nitrogen was used as the nebulizer gas. Data acquisition was performed with a Waters-Micromass MassLynx-Openlynx data system.
• Reversed phase UPLC was carried out on a bridged ethylsiloxane/silica hybrid (BEH) C18 column (1.7 ⁇ m, 2.1 ⁇ 50 mm; Waters Acquity) with a flow rate of 0.8 ml/min.
• Two mobile phases (10 mM ammonium acetate in H 2 O/acetonitrile 95/5; mobile phase B: acetonitrile) were used to run a gradient condition from 95% A and 5% B to 5% A and 95% B in 1.3 minutes and hold for 0.3 minutes.
• An injection volume of 0.5 ⁇ l was used.
• Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
• Reversed phase UPLC (Ultra Performance Liquid Chromatography) was carried out on a Acquity UPLC HSS T3 column (1.8 ⁇ m, 2.1 ⁇ 100 mm; Waters Acquity) with a flow rate of 0.8 ml/min.
• Two mobile phases (A: 10 mM ammonium acetate in H 2 O/acetonitrile 95/5; mobile phase B: acetonitrile) were used to run a gradient condition from 95% A and 5% B to 0% A and 100% B in 2.5 minutes and subsequently to 5% A and 95% B in 0.5 minutes.
• An injection volume of 1 ⁇ l was used.
• Cone voltage was 30 V for positive ionization mode and 30 V for negative ionization mode.
• melting points (m.p.) were determined with a DSC823e (Mettler-Toledo). Melting points were measured with a temperature gradient of 30° C./minute. Maximum temperature was 400° C. Values are peak values.
• Step 1 Synthesis of tert-butyl 3-(2-nitrophenylamino)azetidine-1-carboxylate 15-d
• Step 2 Synthesis of tert-butyl 3-(2-aminophenylamino)azetidine-1-carboxylate 15-c
• Intermediate 21-c was prepared by following an analogous reaction protocol as described for intermediate 15-d using 4-chloro-3-nitropyridine 17-a and thiazol-2-amine as starting material.
• the intermediate 23-b (75 g, 543 mmol) was dissolved in CH 2 Cl 2 (750 ml). The mixture was cooled to 0° C. The phosphorus tribromide (53.6 ml, 570 mmol) was added drop wise keeping the temperature between 0 to 5° C. After addition, the mixture was allowed to warm to 25° C. and stirred for 15 h. The mixture was poured into ice-water. The separated organic layer was washed with brine (2 ⁇ 1500 mL), dried over Na 2 SO 4 , filtered and evaporated under vacuum to yield the title intermediate 23-c (77 g, 71%).
• Step 1 Synthesis of ethyl 5-chloro-1-(3-(methylsulfonyl)propyl)-1H-indole-2-carboxylate 24-b
• Ethyl 5-bromo-1H-indole-2-carboxylate 24-a (2.3 g, 8.6 mmol) was dissolved in DMF (50 mL). The mixture was stirred at room temperature, then sodium hydride 60% suspension in mineral oil (0.52 g, 12.8 mmol) was added. The resulting mixture was stirred at room temperature for 1 hour, then 1-bromo-3-(methylsulfonyl)propane 23-c (2.6 g, 12.8 mmol) was added. The resulting mixture was stirred at room temperature overnight. The mixture was poured in ice/water solution and extracted with ethyl acetate. The organic layer was dried over MgSO 4 and concentrated to yield a brown crude oil. The crude was purified by column chromatography using dichloromethane/methanol to yield the title compound 24-b (3.2 g, 96%) as a white solid.
• Intermediate 34-c was prepared by following an analogous reaction protocol as described for intermediate 15-d using 4-chloro-3-nitropyridine 17-a and pyridin-4-amine as starting material.
• Intermediate 35-c was prepared by following an analogous reaction protocol as described for intermediate 15-d using 4-chloro-3-nitropyridine 17-a and pyrimidin-4-amine as starting material.
• Intermediate 37-c was prepared by following an analogous reaction protocol as described for intermediate 16-d using 1,4-difluoro-2-nitrobenzene 16-a and thiazol-2-amine as starting material.
• Intermediate 38-c was prepared by following an analogous reaction protocol as described for intermediate 16-d using 1,4-difluoro-2-nitrobenzene 16-a and pyridin-4-amine as starting material.
• Intermediate 40-c was prepared by following an analogous reaction protocol as described for intermediate 15-d using 4-chloro-3-nitropyridine 17-a and 4-(trifluoromethoxy)aniline as starting material.
• Intermediate 43-c was prepared by following an analogous reaction protocol as described for intermediate 15-d using 4-chloro-3-nitropyridine 17-a, and oxazol-2-amine as starting material.
• Step 1 synthesis of 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)benzoic acid 48-a
• Step 2 synthesis of methyl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)-benzoate 48-c
• Step 1 synthesis of 2-bromo-6-chloropyridin-3-amine 49-a
• Step 4 synthesis of methyl 5-chloro-1-(4,4,4-trifluorobutyl)-1H-pyrrolo[3,2-b]-pyridine-2-carboxylate 49-d
• Step 5 synthesis of (5-chloro-1-(4,4,4-trifluorobutyl)-1H-pyrrolo[3,2-b]pyridin-2-yl)-methanol 49-e
• Intermediate 50-c was prepared by following an analogous reaction protocol as described for intermediate 15-d using 4-chloro-3-nitropyridine 17-a, and 4-(methylsulfonyl)aniline as starting material.
• Intermediate 51-c was prepared by following an analogous reaction protocol as described for intermediate 15-d using 4-chloro-3-nitropyridine 17-a, and p-toluidine as starting material.
• intermediate 17-d (1.9 g, 6.6 mmol), triphenylphosphine (2.08 g, 7.9 mmol, 1.2 eq) and intermediate 24-c (2 g, 6.6 mmol) were dissolved in tetrahydrofuran (THF) (60 mL).
• THF tetrahydrofuran
• the solution was placed under N 2 atmosphere and diisopropylazodicarboxylate (DIAD) (1.9 mL, 9.9 mmol) was added via syringe.
• DIAD diisopropylazodicarboxylate
• Compound P2 was prepared by following an analogous reaction protocol as described for compound P1 using intermediate 24-c and tert-butyl 3-(5-fluoro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)azetidine-1-carboxylate 5-d as starting material.
• Compound P6 was prepared by an analogous reaction protocol as described for compound P5 using P4 and acetyl chloride as starting material.
• Compound P7 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 24-c and 1-(1-methylcyclopropyl)-1H-imidazo-[4,5-c]pyridin-2(3H)-one 18-c as starting material.
• Compound P8 was prepared by an analogous reaction protocol as described for compound P1 using fragment A-c and 1-tert-butyl-1H-imidazo[4,5-c]pyridin-2(3H)-one 19-c as starting material.
• Step 1 Synthesis of 6-chloro-N 3 -(4,4,4-trifluorobutyl)-pyridine-2,3-diamine 26-b
• Compound P9 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 26-c and 1-(1-methylcyclopropyl)-1H-imidazo-[4,5-c]pyridin-2(3H)-one 18-c as starting material.
• Intermediate 27-a was prepared by an analogous reaction protocol as described for intermediate 26-c using intermediate 26-a and 4-fluorobutanal as starting material.
• Compound P10 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 27-a and 1-(thiazol-6-yl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 21-c as starting material.
• Intermediate 28-a was prepared by an analogous reaction protocol as described for intermediate 24-c using intermediate 24-a and 1-bromo-4-fluorobutane as starting material.
• Compound P11 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 28-a and 1-(thiazol-6-yl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 21-c as starting material.
• Intermediate 30-a was prepared by an analogous reaction protocol as described for intermediate 26-c using intermediate 26-a and 3-methylbutanal as starting material.
• Compound P13 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 30-a and 1-(quinolin-6-yl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 20-c as starting material.
• Step 1 synthesis of ethyl 5-chloro-1-(3-cyanopropyl)-1H-indole-2-carboxylate 31-a
• Ethyl-5-chloroindol-2-carboxylate 24-a (33.55 g, 150 mmol) was dissolved in acetonitrile (600 mL) and stirred at room temperature. Then cesiumcarbonate (73.31 g, 225 mmol) was added and stirring was continued for 30 minutes. 4-Bromobutyronitrile (18.83 mL, 180 mmol) was added in small portions over a period of one hour and stirring was done overnight at ambient temperature. The reaction mixture was filtered and the filtrate was evaporated to dryness. The residue was dissolved in dichloromethane and washed with water. The organic layer was dried over MgSO4, filtered and evaporated. The residue 43.5 g was used as such in the next step 99% yield.
• Step 4 Synthesis of 4-(5-chloro-2-((1-(4-methoxyphenyl)-2-oxo-1H-imidazo[4,5-c]pyridin-3 (2H)-yl)methyl)-1H-indol-1-yl)butanenitrile (P14)
• Compound P15 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 1-(3-fluoro-4-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 45-c as starting material.
• Compound P16 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 30-a and 1-(4-methoxyphenyl)-1H-imidazo-[4,5-c]pyridin-2(3H)-one 22-c as starting material.
• Compound P17 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 49-e and 1-(4-methoxyphenyl)-1H-imidazo[4,5-c]-pyridin-2(3H)-one 22-c as starting material.
• Compound P18 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 30-a and 1-(1-methylcyclopropyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 18-c as starting material.
• Compound P19 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 1-(3,4-dimethoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 32-c as starting material.
• Compound P20 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 1-(4-methoxy-2-methylphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 33-c as starting material.
• Compound P21 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 1-(pyrimidin-2-yl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 53-c as starting material.
• Compound P22 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 30-a and 1-(thiazol-2-yl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 21-c as starting material.
• Compound P23 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 30-a and 1-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 34-c as starting material.
• Compound P24 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 1-(pyrimidin-4-yl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 35-c as starting material.
• Compound P25 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 30-a and 5-fluoro-1-(thiazol-2-yl)-1H-benzo[d]imidazol-2(3H)-one 37-c as starting material.
• Compound P26 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 30-a and 1-(3-fluoropyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 36-c as starting material.
• Compound P27 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 5-fluoro-1-(thiazol-2-yl)-1H-benzo[d]imidazol-2(3H)-one 37-c as starting material.
• Compound P28 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 1-(4-(2-methoxyethoxyl)phenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 39-c as starting material.
• Compound P29 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 1-(4-(trifluoromethoxy)phenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 40-c as starting material.
• Compound P30 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 24-c and 1-(4-chlorophenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 41-c as starting material.
• Compound P31 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 28-a and 1-(quinolin-6-yl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 20-c as starting material.
• Compound P32 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 28-a and 1-(4-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 22-c as starting material.
• Compound P33 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 1-(1-methyl-1H-imidazol-2-yl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 42-c as starting material.
• Compound P34 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 28-a and 1-(4-chlorophenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 41-c as starting material.
• Compound P35 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 24-c and 1-(4-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 22-c as starting material.
• Compound P36 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 1-(1-methyl-1H-pyrazol-3-yl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 44-c as starting material.
• Compound P37 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 1-(oxazol-2-yl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 43-c as starting material.
• Compound P38 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 28-a and 1-(1-methyl-1H-pyrazol-3-yl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 44-c as starting material.
• Compound P39 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 1-(4-chlorophenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 41-c as starting material.
• Compound P40 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 5-fluoro-1-(pyridin-4-yl)-1H-benzo[d]imidazol-2(3H)-one 38-c as starting material.
• Compound P41 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 1-(4-(methylsulfonyl)phenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 50-c as starting material.
• Compound P42 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 1-(3-fluoropyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 36-c as starting material.
• Compound P43 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 1-(quinolin-6-yl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 20-c as starting material.
• Compound P44 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 28-a and 1-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 20-c as starting material.
• Compound P45 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 1-(2-fluoro-4-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 46-c as starting material.
• Compound P46 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 1-p-tolyl-1H-imidazo[4,5-c]pyridin-2(3H)-one 51-c as starting material.
• Compound P47 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 1-(2,4-dimethoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 52-c as starting material.
• Compound P48 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 1-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 34-c as starting material.
• Compound P49 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 1-(thiazol-2-yl)-1H-imidazo[4,5-c]pyridin-2(3H)-one 21-c as starting material.
• Compound P50 was prepared by an analogous reaction protocol as described for compound P1 using intermediate 31-c and 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)benzonitrile 47-c as starting material.
• rgRSV224 virus is an engineered virus that includes an additional GFP gene (Hallak et al, 2000) and was in-licensed from the NIH (Bethesda, Md., USA). Medium, virus- and mock-infected controls were included in each test. Cells were incubated at 37° C. in a 5% CO 2 atmosphere. Three days post-virus exposure, viral replication was quantified by measuring GFP expression in the cells by a MSM laser microscope (Tibotec, Beerse, Belgium). The EC 50 was defined as the 50% inhibitory concentration for GFP expression.
• cytotoxicity of compounds in HeLa cells was determined by measuring the ATP content of the cells using the ATPlite kit (PerkinElmer, Zaventem, Belgium) according to the manufacturer's instructions.
• the CC 50 was defined as the 50% concentration for cytotoxicity.
• Active ingredient (a.i.) as used throughout these examples relates to a compound of Formula (I), including any stereoisomeric form thereof, or a pharmaceutically acceptable addition salt or a solvate thereof; in particular to any one of the exemplified compounds.
• An aqueous suspension is prepared for oral administration so that each milliliter contains 1 to 5 mg of active ingredient, 50 mg of sodium carboxymethyl cellulose, 1 mg of sodium benzoate, 500 mg of sorbitol and water ad 1 ml.
• a parenteral composition is prepared by stirring 1.5% (weight/volume) of active ingredient in 0.9% NaCl solution or in 10% by volume propylene glycol in water.
• active ingredient can be replaced with the same amount of any of the compounds according to the present invention, in particular by the same amount of any of the exemplified compounds.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Virology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Pulmonology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Applications Claiming Priority (5)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=48613635

Family Applications (2)

Family Applications After (1)

Country Status (20)

Cited By (4)

Families Citing this family (5)

Citations (6)

Family Cites Families (24)

• 2013
  • 2013-06-14 PL PL13728404T patent/PL2864323T3/pl unknown
  • 2013-06-14 DK DK13728404.8T patent/DK2864323T3/en active
  • 2013-06-14 US US14/407,134 patent/US20150111868A1/en not_active Abandoned
  • 2013-06-14 JP JP2015516621A patent/JP6259451B2/ja active Active
  • 2013-06-14 WO PCT/EP2013/062322 patent/WO2013186333A1/en active Application Filing
  • 2013-06-14 CA CA2873920A patent/CA2873920C/en active Active
  • 2013-06-14 CN CN201380031144.7A patent/CN104540817B/zh active Active
  • 2013-06-14 TW TW102121025A patent/TWI643850B/zh not_active IP Right Cessation
  • 2013-06-14 SI SI201330706T patent/SI2864323T1/sl unknown
  • 2013-06-14 EP EP13728404.8A patent/EP2864323B1/en active Active
  • 2013-06-14 HU HUE13728404A patent/HUE033848T2/en unknown
  • 2013-06-14 AR ARP130102108 patent/AR091455A1/es active IP Right Grant
  • 2013-06-14 EA EA201590022A patent/EA028240B1/ru not_active IP Right Cessation
  • 2013-06-14 PT PT137284048T patent/PT2864323T/pt unknown
  • 2013-06-14 LT LTEP13728404.8T patent/LT2864323T/lt unknown
  • 2013-06-14 AU AU2013276519A patent/AU2013276519B2/en not_active Ceased
  • 2013-06-14 KR KR1020157000509A patent/KR102092612B1/ko active IP Right Grant
  • 2013-06-14 ES ES13728404.8T patent/ES2632914T3/es active Active
• 2016
  • 2016-01-08 US US14/991,815 patent/US9845321B2/en active Active
• 2017
  • 2017-07-10 HR HRP20171050TT patent/HRP20171050T1/hr unknown
  • 2017-07-18 CY CY20171100765T patent/CY1119289T1/el unknown

Patent Citations (6)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events